Categories
Cardiovascular
Diagnostics
Endocrinology
Health Insurance
Medical Devices
Mental Health
Nutrition
Oncology
Public Health
Sexual Health
buy vibrator.
Popular Articles

Recipients Of HIV/AIDS Programs Aid Expected To Feel Crunch Of Global Economic Crisis
At the 2009 HIV Implementers" Meeting in Namibia Thursday, Paul DeLay, deputy executive director of UNAIDS, said the global economic crisis will impact countries who receive international aid for HIV/AIDS programs, so recipients of such aid should identify priorities for their programs, the China Post reports (China Post, 6/12).
pharmacy online
UK's Poorest Twice As Likely To Have Diabetes And Its Complications
The poorest people in the UK are 2.5 times more likely to have diabetes at any age than the average person, a new Diabetes UK report reveals today. And once they have the condition, those in the most deprived homes are twice as likely to develop complications of diabetes as those in the least deprived.
News of the day
Sebelius, DeParle Ready To Tackle Health Care Overhaul
The friendship between "working moms" Kathleen Sebelius and Nancy-Ann DeParle "could pay big dividends for President Obama now," USA Today reports. The two have a lot in common in the policy world as well. Sebelius, the secretary of Health and Human Services, and DeParle, director of the White House Office of Health Reform, "first met at the White House mess in 1997, during the battle for a patients" bill of rights to combat the constraints of managed care." Their relationship was then "built over a dozen years on topics ranging from the children"s health insurance program to raising their own children. Now, they are the "tag team for Obama"s most ambitious domestic policy goal: an overhaul of the nation"s health care system."
Medical Devices

Amarillo Biosciences And CytoPharm Announce Start Of Enrollment For Hepatitis C Study In Taiwan

Amarillo Biosciences, Inc. (ABI) (OTCBB: AMAR) and CytoPharm, Inc. today jointly announced the start of enrollment for a study of ABI"s oral interferon-alpha lozenges for chronic hepatitis C virus infection. The aim of the trial is to reduce the virologic relapse rate for those patients who have completed the standard combination therapy, which consists of high dose injectable interferon-alpha and Ribavirin. Although most patients respond to the standard therapy, up to 50% of those with certain "high-risk" viral genotypes relapse after treatment. The study will be conducted under the direction of Dr. Chau-Ting Yeh at the Chang Gung Memorial Hospital in Taipei, Taiwan. A total of 165 patients who test positive for a "high-risk" hepatitis C viral genotype will receive one of two different doses of human interferon-alpha or placebo given daily for 24 weeks. Following completion of treatment, patients will be monitored for relapse for an additional 24 weeks. Full study enrollment is expected by the end of the year with study completion targeted for the 4th quarter of 2010. Approximately 170 million people are chronically infected with hepatitis C virus worldwide, with an additional 3-4 million cases occurring each year. The incidence of cirrhosis in chronic hepatitis C patients is 10 to 20%, and 1 to 5% develop liver cancer. In addition to sexual and perinatal transmission, hepatitis C virus infection is common following direct contact with contaminated blood, typically due to inadequately sterilized needles and syringes. Currently, there is no effective vaccine against hepatitis C virus. Separately, the companies announced that CytoPharm is planning a study of oral interferon lozenges in the treatment of influenza to be launched during the 2009/2010 flu season in Taiwan. About Amarillo Biosciences, Inc. Amarillo Biosciences, Inc. is a U.S. biotechnology firm operating in global partnership with the Hayashibara Group, which also holds 7% of Amarillo Biosciences" shares and has provided over $18 million in loans, grants and equity investments. The Company"s primary focus is extensive and ongoing R&D into the use of low-dose, orally administered interferon as a treatment for a variety of conditions, including influenza, hepatitis C, chronic cough, and opportunistic infections in patients who are HIV positive. In its 25-year history, the Company has invested nearly $40 million to establish oral interferon as a therapeutic agent. The majority of those funds were invested in clinical trials in an effort to achieve FDA approval for interferon. Additional information is available on the web site at http://www.amarbio.com/. CytoPharm


Add your comment:
Name:
Site address: http://
Your message:
Enter today\\\\'s date, 2 digits
(spam protection):

© Copyright 2009